Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
18.37
-0.40 (-2.13%)
At close: Oct 8, 2025, 4:00 PM EDT
19.22
+0.85 (4.63%)
After-hours: Oct 8, 2025, 5:30 PM EDT
Neuphoria Therapeutics Revenue
In the fiscal year ending June 30, 2025, Neuphoria Therapeutics had annual revenue of $15.65M. Neuphoria Therapeutics had revenue of $-13.27K in the quarter ending June 30, 2025.
Revenue (ttm)
$15.65M
Revenue Growth
n/a
P/S Ratio
1.91
Revenue / Employee
$652,060
Employees
24
Market Cap
43.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 15.65M | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | - | - | - |
| Jun 30, 2022 | 4.17M | 3.48M | 499.60% |
| Jun 30, 2021 | 695.81K | -1.37M | -66.32% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
NEUP News
- 9 days ago - Neuphoria Provides Fiscal Year-End 2025 Financial Results and Business Updates - GlobeNewsWire
- 4 weeks ago - Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD) - GlobeNewsWire
- 5 weeks ago - Neuphoria Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 months ago - Neuphoria to Present at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting - GlobeNewsWire
- 5 months ago - Neuphoria Provides First Quarter 2025 Business Updates - GlobeNewsWire
- 6 months ago - Neuphoria Provides a Review of 2024 and Highlights 2025 Plans - GlobeNewsWire
- 7 months ago - Neuphoria Therapeutics to Ring the Nasdaq Opening Bell on March 3rd, 2025 - GlobeNewsWire
- 8 months ago - Neuphoria Therapeutics Inc. to Receive $15M Milestone Payment from Merck - GlobeNewsWire